[Click eStock] "NewG Lab's Developing Anticancer Agent Draws Attention"

[Asia Economy Reporter Hyungsoo Park] Hanyang Securities analyzed on the 8th that attention should be paid to Newgelab's metabolic anticancer agent 'KAT'.

Byungyong Oh, a researcher at Hanyang Securities, explained, "Cancer cells produce most of their energy through glycolysis," adding, "Inevitably, lactic acid is generated, and there needs to be a pathway for lactic acid to be expelled outside the cell."

He continued, "The MCT channel, which serves as this pathway, is specifically open only in cancer cells," and added, "3BP, the raw material of KAT, is a toxic substance whose molecular structure is very similar to lactic acid and can enter cancer cells through the MCT channel."

He emphasized, "It cannot enter normal cells," and stated, "Theoretically, 3BP only enters cancer cells, inhibits hexokinase 2, blocks glycolysis, and cuts off energy production in 60% of cancer cells."

Researcher Oh said, "Dr. Younghee Ko is the co-CEO and CSO of Newgelab's U.S. branch," and "Dr. Peter Pedersen of Johns Hopkins also serves as a scientific advisory board member of Newgelab."

He introduced, "There are already many cases of actual patients treated with KAT," and said, "Dr. Younghee Ko treated dozens of cancer patients with various cancer types by utilizing the U.S. expanded access program for treatment purposes."

Researcher Oh analyzed, "Unlike existing targeted therapies, metabolic anticancer agents can be widely used for all solid tumors," and added, "Dr. Younghee Ko holds decades of research results and patents on formulations that reduce the toxicity of 3BP and improve stability, as well as delivery methods and concentrations to cancer cells."

This content was produced with the assistance of AI translation services.